TABLE OF CONTENTS

	Page
Acknowledgements	iii
English Abstract	iv
Thai Abstract	vi
List of Tables	xi
List of Figures	xiv
List of Abbreviations	xvii
Chapter 1 Introduction	1
Chapter 2 Literature review	6
2.1 Anatomy and function of the eye	6
2.2 Nasolachrymal drainage system	8
2.3 Physiological Considerations	9
2.4 Pharmacokinetic Considerations	11
2.5 New Drug Delivery Systems	12
2.6 Chitosan	12
2.7 Bacterial keratitis	16
2.7.1 Some common ocular pathogens	16
2.7.1.1 Gram-positive cocci	16
2.7.1.2 Gram-negative cocci	20
2.7.1.3 Gram-positive rods	20
2.7.1.4 Gram-negative rods	21
2.7.2 Clinical Features of bacterial keratitis 2.7.3 Treatment	22 23
2.7.3.1 Routes of administration to the eye 2.7.3.2 Dosage forms	24 24
2.7.3.3 Preparations for topical	25
administration	
2.8 Vancomycin	27

	Page
Chapter 3 Materials and methods	29
3.1 Materials	29
3.1.1 Chemicals	29
3.1.2 Animals	29
3.1.3 Microorganism	29
3.1.4 Equipments	30
3.1.5 Other Materials	30
3.2 Methods	30
3.2.1 Determination of loss on drying	30
3.2.2 Determination of viscosity-average molecular	31
weight (\overline{M}_{ν})	
3.2.3 Determination of degree of deacetylation	37
3.2.4 Preparation and characterization of chitosan solution	37
3.2.5 Preparation of ophthalmic formulations	40
3.2.5.1 Design of compatibility and stability studies	40
3.2.5.2 Validation of the UV spectrophotometer	41
3.2.5.3 Determination of vancomycin concentration	41
and pH	
3.2.6 Minimum inhibitory concentration analysis	41
3.2.7 Kinematic viscosity measurements	43
3.2.8 Pharmacokinatics of topically applied vancomycin	44
adams in rabbit eyes ng a gl a gl a gl a	1 1
3.2.8.1 Topical administration and sampling	44
Copyright 3.2.8.2 Determination of vancomycin University concentration in tears	46
Chapter 4 Results and discussion Chapter 4 Result	48
4.1 Loss on drying of chitosan	48
4.2 Viscosity-average molecular weight (\overline{M}_{ν}) of chitosan	48
4.3 Degree of deacetylation of chitosan	50

	Page
4.4 Preparation of chitosan solution	51
4.4.1 Viscosity stability of 0.1% chitosan solution	54
4.4.2 Viscosity stability of 0.3% chitosan solution	56
4.5 Preparation ophthalmic formulations	61
4.5.1 Compatibility and stability studies	61
4.5.2 Validation of the UV spectrophotometer	62
4.5.3 Stability of vancomycin eye drops at 50 mg/ml in	72
each vehicle	
4.6 Minimum inhibitory concentrations of vancomycin at 50	75
mg/ml in Tears Naturale II TM , sodium chloride and	
chitosan solutions stored at different temperatures over	
time	
4.7 Kinematic viscosity measurements	79
4.8 Pharmacokinetics of topically applied vancomycin	81
in rabbit eyes	
Chapter 5 Summary and conclusion	93
References	95
Appendices	105
Appendix A The raw data of viscosity-average molecular	106
weight (\overline{M}_{ν}) of chitosan were determined by	
dilute-solution no 2 and 3.	
Appendix B The raw data of assay validation reports	110
Appendix C Storage Temperature (United States Pharmacopeia)	126
Appendix D Terms describe of the pharmacokinetics	128
Appendix E Certificate of approval for use of animals	131
Faculty of Medicine, Chiang Mai University	e d
Curriculum Vitae	133

LIST OF TABLES

Table	09181945	Page
2.1	Forms of chitosan investigated in ophthalmology	1 age 14
2.2	Micro-organisms isolated from corneal specimens	17
2.3	Risk factors for corneal ulcers and typical organisms	18
2.5	involved	10
		10
2.4	Frequency of predisposing risk factors in microbial	19
	keratitis	
2.5	Preparing fortified topical antibiotics	24
3.1	Definitions and nomenclature of dilute-solution viscosity	34
	quantities	
3.2	Feldman buffer for ophthalmic preparations	39
3.3	Composition of each formulation	40
3.4	Scheme for preparing dilutions of vancomycin to be used	42
	in Mueller-Hinton broth (MHB) dilution susceptibility	
	tests	
4.1	Weight data and calculated loss on drying of chitosan	48
4.2	Dilute-solution viscosity data and calculated parameters	49
	for chitosan solution at $25.0 \pm 0.1^{\circ}$ C (Run No.1)	
4.3	Experimental results and calculated degrees of	50
adana	deacetylation (DD)	1U
4.4	Preparation of 0.1% and 0.3% chitosan solutions by	52
Copyrigh	using Feldman buffer for ophthalmic preparations	ity
4.5	pH Stability of 0.1% and 0.3% chitosan solutions	53
4.6	Viscosity stability of 0.1% chitosan solution	54
4.7	Viscosity stability of 0.3% chitosan solution	56

Table		Page
4.8	Compatibility and stability studies of vancomycin eye	61
	drops at 50 mg/ml in Tears Naturale II TM , 0.9% sodium	
	chloride and the 0.1% and 0.3% chitosan solutions	
4.9	UV spectrophotometric scan of standard vancomycin in	63
	Tears Naturalle II TM and Tears Naturalle II TM	
4.10	UV spectrophotometric scan of standard vancomycin in	64
9	0.1% chitosan and 0.1% chitosan	
4.11	UV spectrophotometric scan of standard vancomycin in	65
	0.9% sodium chloride and 0.9% sodium chloride	
4.12	Calibration of standard vancomycin in Tears Naturale	66
-374		
4.13	Calibration of standard vancomycin in 0.1 % chitosan	67
4.14	Calibration of standard vancomycin in 0.3 % chitosan	68
4.15	Calibration of standard vancomycin in 0.9 % sodium	69
T	chloride	
4.16	Interday assay validation of standard vancomycin in each	70
, in the second s	vehicle	
4.17	Intraday assay validation of standard vancomycin in each	71
	vehicle	
4.18	Recovery validation of standard vancomycin in each	71
	vehicle	
4.19	Lower limit of standard vancomycin in each vehicle	72
	The pH of vancomycin eye drops at 50 mg/ml in each	73
Co _{4.2} righ	vehicle Percentage of the labeled amounts of vancomycin eye	76
	drops at 50 mg/ml in each vehicle	
4.22	Minimum inhibitory concentrations of vancomycin at 50	78
	mg/ml in Tears Naturale II TM , sodium chloride and	
	chitosan solutions stored at different temperatures over	
	time	

Table		Page
4.23	Comparison of the kinematic viscosity, v , of various	79
	solvents and vancomycin at 50 mg/ml in solutions at	
	25°C	
4.24	Control test of vancomycin	81
4.25	Concentration of vancomycin at 50 mg/ml in Tears	82
	Naturale II TM in tear film	
4.26	Concentration of vancomycin at 50 mg/ml in 0.1%	83
	chitosan in tear film	
4.27	Concentration of vancomycin at 50 mg/ml in 0.3%	84
	chitosan in tear film	
4.28	Concentration of vancomycin at 50 mg/ml in normal	85
505	saline solution (NSS) in tear film	
4.29	Areas under the curves of vancomycin at 50 mg/ml	86
Q	$0 \rightarrow 30$ minutes for the range of vehicles used	
4.30	Areas under the curves of vancomycin at 50 mg/ml	87
- J	$0 \rightarrow 120$ minutes for the range of vehicles used	
	ALUNIVERSI	
	AI UNIVER	

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่ Copyright[©] by Chiang Mai University All rights reserved

LIST OF FIGURES

Figure	1918191 BB	Page
1.1	Chemical structure of chitosan	2
1.2	Chemical structure of vancomycin	4
2.1	Anatomy of the eye	6
2.2	Nasolachrymal drainage system	9
3.1	Heating vacuum desiccator	31
3.2	Viscometers commonly used in dilute-solution	32
	viscometry	
3.3	Reduced and inherent viscosity-concentration plots (data	35
	from this research)	
3.4	The Schott-Gerate AVS Automatic Viscosity Measuring	36
E	System used in dilute-solution viscometry showing, from	
5	left to right, the Ubbelohde viscometer, main control	
, in the second s	unit, and constant temperature water bath	
3.5	Preparation of chitosan solution	38
3.6	Osmomat 030	38
3.7	Growth (not clear) and no growth (clear) of bacteria	43
3.8	The animals were maintained under conventional,	44
6.18.06	standardized conditions in a single cage with free access	
adant	to pelleted food and drinking water	nIJ
3.9	Preparation of rabbits for applying eye drops	45
3.10	Eye drops instilled into the rabbit's eye	45
3.11	Tear samples were obtained using 2.0 µl of calibrated	46
	glass capillaries (microcaps Drummond TM)	
3.12	Fluorescent polarization immunoassay (TDx-FLx System	47
	Abbott, USA)	

Figure		Page
4.1	Graph of reduced viscosity, η_{red} , and inherent viscosity,	50
	η_{inh} , against concentration (Run No. 1)	
4.2	Variations in intrinsic viscosity,[η], of the 0.1% w/v	55
	chitosan solution with autoclaving and storage time at	
	different temperatures	
4.3	Variations in intrinsic viscosity,[η], of the 0.1% w/v	55
	chitosan solution with storage time only at different	
	temperatures	
4.4	Variations in intrinsic viscosity,[η], of the 0.3% w/v	57
	chitosan solution with autoclaving and subsequent	
502	storage time at different temperatures	
4.5	Variations in intrinsic viscosity,[η], of the 0.3% w/v	57
	chitosan solution with storage time only at different	
	temperatures	
4.6	UV spectrophotometric scan (in graph) of standard	63
	vancomycin in Tears Naturalle II TM and Tears Naturalle	
	IITM	
4.7	UV spectrophotometric scan (in graph) of standard	64
	vancomycin in 0.1% chitosan and 0.1% chitosan	
4.8	UV spectrophotometric scan (in graph) of standard	65
	vancomycin in 0.9% sodium chloride and 0.9% sodium	
ลิสสิทธิ์	chloride	711
4.9	Calibration curve of standard vancomycin in Tears	66
Copyrig	Naturale II TM no. 1 Chiang Mai University	sity
4.10	Calibration curve of standard vancomycin in 0.1%	67
	chitosan no. 1	e u
4.11	Calibration curve of standard vancomycin in 0.3%	68
	chitosan no.1	
4.12	Calibration curve of standard vancomycin in 0.9%	69
	sodium chloride no. 1	

Figure		Page
4.13	The pH graph of vancomycin eye drops at 50 mg/ml in	74
	each vehicle	
4.14	Percentage graph of the labeled amounts of vancomycin	77
	eye drops at 50 mg/ml in each vehicle	
4.15	Comparison of the kinematic viscosity, v , of various	80
	solvents and vancomycin at 50 mg/ml in solutions at	
9	25°C by bar graph	
4.16	Concentration-time profiles of vancomycin at 50 mg/ml	82
	in Tears Naturale II in tear film (6 samples)	
4.17	Concentration-time profiles of vancomycin at 50 mg/ml	83
24	in 0.1% chitosan solution in tear film (6 samples)	
4.18	Concentration-time profiles of vancomycin at 50 mg/ml	84
	in 0.3% chitosan solution in tear film (6 samples)	
4.19	Concentration-time profiles of vancomycin at 50 mg/ml	85
E	in 0.9% sodium chloride solution in tear film (6 samples)	
4.20	Area under the curve of vancomycin at 50 mg/ml in the	88
- I V	various vehicles used	
	MAI UNIVERSIT	

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่ Copyright[©] by Chiang Mai University All rights reserved

LIST OF ABBREVIATIONS

